review glp 1 GLP-1 receptor agonists show promise in treating substance use disorders Frontiers | Exploring the multifaceted

The tolerability and safety of alternative dosing regimens also require clinical validation

Both telehealth platforms can connect patients with licensed healthcare providers and, if eligible, GLP-1 prescription medications

Bupropion/Naltrexone The combination of sustained-release (SR) bupropion and naltrexone has been shown to be effective in the treatment of obesity through their synergistic effects on appetite regulation and energy expenditure

A comprehensive spatio-cellular map of the human hypothalamus

Over the last 40 to 50 years, the indications for upper GI surgery have shifted from benign ulcer disease to oncological causes and severe obesity (bariatric surgery)

Furthermore, pharmaceutical giants Pfizer and Amgen are not far behind, with promising GLP-1 drugs in clinical development